Nasdaq
Nasdaq Affirms OpGen's Delisting Decision
The molecular diagnostics developer has appealed the decision and said its stock will continue to trade on the OTC markets in the meantime.
T2 Biosystems Receives Delisting Notice From Nasdaq
The company has requested a hearing and paid a $20,000 fee to delay its delisting determination until Jan. 9, 2025.
Quantum-Si Regains Compliance With Nasdaq Listing Requirements
As of Dec. 4, the firm’s stock had closed above $1 per share for 10 consecutive business days, bringing it back into compliance with the Nasdaq's rules.
Nasdaq to Delist Centogene
The German firm did not appeal the decision and will be delisted after having failed to achieve certain milestones to retain its status as a listed company.
OpGen Shares Suspended From Trading on Nasdaq
The suspension comes as the molecular diagnostics firm struggles to meet the Nasdaq's minimum stockholders’ equity requirement.